Literature DB >> 24942754

Performance of the standardised MedDRA® queries for case retrieval in the French spontaneous reporting database.

Hélène Géniaux1, Denise Assaf, Ghada Miremont-Salamé, Bénédicte Raspaud, Amandine Gouverneur, Philip Robinson, Antoine Pariente, Francesco Salvo.   

Abstract

OBJECTIVE: The objective of this study was to evaluate the performance of Standardised MedDRA® Queries (SMQs) in adverse drug reaction (ADR) identification.
METHODS: ADR cases included in the last complete year of the French Pharmacovigilance database for research were used to test four SMQs (narrow and broad): agranulocytosis, demyelination, osteonecrosis and psychosis. Reference cases were identified by free-text search and validated by two authors. Sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV) of narrow and broad searches of each SMQ were calculated and reported as proportions with 95% exact confidence interval (CI).
RESULTS: Among 20,830 cases reported in 2009, 337 validated cases of agranulocytosis, 17 of demyelination, 52 of osteonecrosis and 230 of psychosis were included in the reference sets. Estimations of SMQ narrow search performance were as follows: Se 62.9% (95% CI 57.5-68.1) and PPV 46.8% (95% CI 42.1-51.5) for agranulocytosis; Se 88.2% (95% CI 63.6-98.5) and PPV 34.1% (95% CI 20.5-49.9) for demyelination; Se 94.2% (95% CI 84.1-98.8) and PPV 74.2% (95% CI 62.0-84.2) for osteonecrosis; and Se 75.1% (95% CI 69.0-80.6) and PPV 87.8% (95% CI 82.3-92.0) for psychosis. Results obtained using the broad search were similar except for PPV concerning osteonecrosis (52.7% [95% CI 42.1-63.1]) and psychosis (61.4% [95% CI 55.7-66.8]). For all selected SMQs, Sp and NPV were greater than 98% for both narrow and broad searches.
CONCLUSION: Heterogeneous performance of SMQs for case retrieval was found and seems to be related to the characteristics of the condition of interest. It could therefore be expected that for other SMQs, performance may be affected in the same manner.

Entities:  

Mesh:

Year:  2014        PMID: 24942754     DOI: 10.1007/s40264-014-0187-2

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  10 in total

1.  A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions.

Authors:  Eugène P van Puijenbroek; Andrew Bate; Hubert G M Leufkens; Marie Lindquist; Roland Orre; Antoine C G Egberts
Journal:  Pharmacoepidemiol Drug Saf       Date:  2002 Jan-Feb       Impact factor: 2.890

2.  Effects of coding dictionary on signal generation: a consideration of use of MedDRA compared with WHO-ART.

Authors:  Elliot G Brown
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

3.  Standardised MedDRA queries: their role in signal detection.

Authors:  Patricia Mozzicato
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

4.  Tabulation and analysis of pharmacovigilance data using the medical dictionary for regulatory activities.

Authors:  E Brown Bmedsci Mb Chb Mrcgp Ffpm; S Douglas Bsc
Journal:  Pharmacoepidemiol Drug Saf       Date:  2000-11       Impact factor: 2.890

5.  Evaluation of an ontological resource for pharmacovigilance.

Authors:  Marie-Christine Jaulent; Iulian Alecu
Journal:  Stud Health Technol Inform       Date:  2009

6.  Grouping pharmacovigilance terms with semantic distance.

Authors:  Marie Dupuch; Magnus Lerch; Anne Jamet; Marie-Christine Jaulent; Reinhard Fescharek; Natalia Grabar
Journal:  Stud Health Technol Inform       Date:  2011

7.  Grouping the pharmacovigilance terms with a hybrid approach.

Authors:  Marie Dupuch; Laëtitia Dupuch; Amandine Perinet; Thierry Hamon; Natalia Grabar
Journal:  Stud Health Technol Inform       Date:  2012

8.  Influence of the MedDRA hierarchy on pharmacovigilance data mining results.

Authors:  Ronald K Pearson; Manfred Hauben; David I Goldsmith; A Lawrence Gould; David Madigan; Donald J O'Hara; Stephanie J Reisinger; Alan M Hochberg
Journal:  Int J Med Inform       Date:  2009-02-18       Impact factor: 4.046

Review 9.  Drug-induced musculoskeletal disorders.

Authors:  Bernard Bannwarth
Journal:  Drug Saf       Date:  2007       Impact factor: 5.228

10.  Exploitation of semantic methods to cluster pharmacovigilance terms.

Authors:  Marie Dupuch; Laëtitia Dupuch; Thierry Hamon; Natalia Grabar
Journal:  J Biomed Semantics       Date:  2014-04-16
  10 in total
  5 in total

1.  A Method for the Minimization of Competition Bias in Signal Detection from Spontaneous Reporting Databases.

Authors:  Mickael Arnaud; Francesco Salvo; Ismaïl Ahmed; Philip Robinson; Nicholas Moore; Bernard Bégaud; Pascale Tubert-Bitter; Antoine Pariente
Journal:  Drug Saf       Date:  2016-03       Impact factor: 5.606

2.  Identifying adverse drug reactions from free-text electronic hospital health record notes.

Authors:  Arthur Wasylewicz; Britt van de Burgt; Aniek Weterings; Naomi Jessurun; Erik Korsten; Toine Egberts; Arthur Bouwman; Marieke Kerskes; René Grouls; Carolien van der Linden
Journal:  Br J Clin Pharmacol       Date:  2021-10-13       Impact factor: 3.716

3.  Drug-Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data.

Authors:  Wajd Alkabbani; Ryan Pelletier; Michael A Beazely; Youssef Labib; Breanna Quan; John-Michael Gamble
Journal:  Drug Saf       Date:  2022-03-05       Impact factor: 5.228

4.  Patterns of use and impact of standardised MedDRA query analyses on the safety evaluation and review of new drug and biologics license applications.

Authors:  Lin-Chau Chang; Riaz Mahmood; Samina Qureshi; Christopher D Breder
Journal:  PLoS One       Date:  2017-06-01       Impact factor: 3.240

5.  Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS).

Authors:  Santa Cirmi; Asmae El Abd; Louis Letinier; Michele Navarra; Francesco Salvo
Journal:  Cancers (Basel)       Date:  2020-03-30       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.